As of June 30, 2026, China Resources Pharmaceutical Group Ltd. carries a market capitalization of 3.03B, placing it among publicly traded companies globally. Its enterprise value stands at 18.32B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 3.03B |
| Enterprise Value | 18.32B |
China Resources Pharmaceutical Group Ltd.'s next confirmed earnings release is scheduled for March 24, 2027.
| Earnings Date | 3/24/2027 |
As of June 30, 2026, China Resources Pharmaceutical Group Ltd. has 6.28B shares outstanding.
| Shares Outstanding | 6.28B |
These figures are as of June 30, 2026.
| PB Ratio | 0.44 |
| P/TBV Ratio | 1.35 |
As of June 30, 2026, China Resources Pharmaceutical Group Ltd. maintains a current ratio of 1.43, meaning it holds 1.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 1.43 |
| Quick Ratio | 0.18 |
| Debt / Equity | 65.78 |
These figures cover the twelve months ended June 30, 2026.
| Employee Count | 85,600.00 |
As of the close on November 17, 2026, China Resources Pharmaceutical Group Ltd.'s stock has declined approximately 3.70% over the past 52 weeks. The 50-day moving average sits at 0.50, while the 200-day moving average is 0.53.
| 52-Week Price Change | -3.70% |
| 50-Day Moving Average | 0.50 |
| 200-Day Moving Average | 0.53 |
As of June 30, 2026, China Resources Pharmaceutical Group Ltd. holds 3.42B in cash and equivalents against 10.13B in total debt, resulting in a net debt position of 7.97B. Total book value stands at 6.81B, with working capital of 8.11B providing operational flexibility.
| Cash & Cash Equivalents | 3.42B |
| Total Debt | 10.13B |
| Net Debt | 7.97B |
| Equity (Book Value) | 6.81B |
| Book Value Per Share | 1.08 |
| Working Capital | 8.11B |
Already premium?